AAG
LUCD icon

Accordant Advisory Group’s Lucid Diagnostics LUCD Stock Holding History

Accordant Advisory Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4K Hold
14,300
– – 0.01% 140
2025
Q4 		$15.6K Buy
14,300
+9,800
+218% +$11K 0.01% 124
2025
Q3 		$4.54K Buy
+4,500
New +$4.91K ﹤0.01% 146

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Accordant Advisory Group's LUCD Position: Q1 2026 in Review

Accordant Advisory Group held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 14,300 shares worth $16.4K. The position accounts for 0.01% of the portfolio, ranked #140.

Accordant Advisory Group first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Accordant Advisory Group held 14,300 shares of Lucid Diagnostics worth $16.4K as of Q1 2026.
  • Accordant Advisory Group left its Lucid Diagnostics share count unchanged in Q1 2026.
  • Lucid Diagnostics made up 0.01% of Accordant Advisory Group's portfolio in Q1 2026, its #140 holding.
  • Accordant Advisory Group first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Accordant Advisory Group's 13F filing for Q1 2026, filed 11 May 2026.